Molecular mechanisms and novel therapeutic approaches to rhabdomyolysis-induced acute kidney injury

Kidney and Blood Pressure Research

Volumn 40, Issue 5, 2015, Pages 520-532

  Panizo, Nayara ^a   Rubio Navarro, Alfonso ^b   Amaro Villalobos, Juan Manuel ^b   Egido, Jesús ^b   Moreno, Juan Antonio ^b  

^a B BRAUN Avitum   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Acute kidney injury; Chronic kidney disease; Myoglobin; Rhabdomyolysis

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BIOLOGICAL MARKER; IRON CHELATING AGENT; KIM 1 PROTEIN; MYOGLOBIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ACUTE KIDNEY FAILURE; APOPTOSIS; CHELATION THERAPY; CONTROL STRATEGY; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; INFLAMMATION; KIDNEY BLOOD FLOW; MESENCHYMAL STEM CELL TRANSPLANTATION; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; REVIEW; RHABDOMYOLYSIS; SIGNAL TRANSDUCTION; STRATEGIC PLANNING; TREATMENT OUTCOME; VASOCONSTRICTION; ACUTE KIDNEY INJURY; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; SKELETAL MUSCLE;

ACUTE KIDNEY INJURY; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; HUMANS; IRON CHELATING AGENTS; MUSCLE, SKELETAL; MYOGLOBIN; OXIDATIVE STRESS; RHABDOMYOLYSIS;

EID: 84945156706     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000368528     Document Type: Review

References (90)

1. Bosch X, Poch E, Grau JM: Rhabdomyolysis and acute kidney injury. N Engl J Med 2009;361:62-72.
2. Bagley WH, Yang H, Shah KH: Rhabdomyolysis. Intern Emerg Med 2007;2:210-218.
3. Sauret JM, Marinides G, Wang GK: Rhabdomyolysis. Am Fam Physician 2002;65:907-912.
4. Holt SG, Moore KP: Pathogenesis and treatment of renal dysfunction in rhabdomyolysis. Intensive Care Med 2001;27:803-811.
5. Zimmerman JL, Shen MC: Rhabdomyolysis. Chest 2013;144:1058-1065.
6. de Meijer AR, Fikkers BG, de Keijzer MH, van Engelen BG, Drenth JP: Serum creatine kinase as predictor of clinical course in rhabdomyolysis: a 5-year intensive care survey. Intensive Care Med 2003;29:1121-1125.
7. Wen X, Peng Z, Kellum JA: Pathogenesis of acute kidney injury: effects of remote tissue damage on the kidney. Contrib Nephrol 2011;174:129-137.
8. Belliere J, Casemayou A, Ducasse L, Zakaroff-Girard A, Martins F, Iacovoni JS, Guilbeau-Frugier C, Buffin-Meyer B, Pipy B, Chauveau D, Schanstra JP, Bascands JL: Specific Macrophage Subtypes Influence the Progression of Rhabdomyolysis-Induced Kidney Injury. J Am Soc Nephrol 2014, DOI 10. 1681/ ASN. 2014040320
9. Khan FY: Rhabdomyolysis: a review of the literature. Neth J Med 2009;67:272-283.
10. Gburek J, Birn H, Verroust PJ, Goj B, Jacobsen C, Moestrup SK, Willnow TE, Christensen EI: Renal uptake of myoglobin is mediated by the endocytic receptors megalin and cubilin. Am J Physiol Renal Physiol 2003;285:F451-458.
11. Boutaud O, Roberts LJ, 2nd: Mechanism-based therapeutic approaches to rhabdomyolysis-induced renal failure. Free Radic Biol Med 2011;51:1062-1067.
12. Kim SH, Chang JW, Kim SB, Park SK, Park JS, Lee SK: Myoglobin induces vascular cell adhesion molecule-1 expression through c-Src kinase-activator protein-1/nuclear factor-kappaB pathways. Nephron Exp Nephrol 2010;114:e48-60.
13. Petejova N, Martinek A: Acute kidney injury due to rhabdomyolysis and renal replacement therapy: a critical review. Crit Care 2014;18:224.
14. Wijayanti N, Katz N, Immenschuh S: Biology of heme in health and disease. Curr Med Chem 2004;11:981-986.
15. Moore KP, Holt SG, Patel RP, Svistunenko DA, Zackert W, Goodier D, Reeder BJ, Clozel M, Anand R, Cooper CE, Morrow JD, Wilson MT, Darley-Usmar V, Roberts LJ, 2nd: A causative role for redox cycling of myoglobin and its inhibition by alkalinization in the pathogenesis and treatment of rhabdomyolysis-induced renal failure. J Biol Chem 1998;273:31731-31737.
16. Reeder BJ, Wilson MT: Hemoglobin and myoglobin associated oxidative stress: from molecular mechanisms to disease States. Curr Med Chem 2005;12:2741-2751.
17. Moreno JA, Martin-Cleary C, Gutierrez E, Toldos O, Blanco-Colio LM, Praga M, Ortiz A, Egido J: AKI associated with macroscopic glomerular hematuria: clinical and pathophysiologic consequences. Clin J Am Soc Nephrol 2012;7:175-184.
18. Vuletich JL, Osawa Y, Aviram M: Enhanced lipid oxidation by oxidatively modified myoglobin: role of protein-bound heme. Biochem Biophys Res Commun 2000;269:647-651.
19. Jang HR, Rabb H: The innate immune response in ischemic acute kidney injury. Clin Immunol 2009;130:41-50.
20. Gonzalez-Michaca L, Farrugia G, Croatt AJ, Alam J, Nath KA: Heme: a determinant of life and death in renal tubular epithelial cells. Am J Physiol Renal Physiol 2004;286:F370-377.
21. Moreno JA, Martin-Cleary C, Gutierrez E, Rubio-Navarro A, Ortiz A, Praga M, Egido J: Haematuria: the forgotten CKD factor Nephrol Dial Transplant 2012;27:28-34.
22. Wagener FA, Feldman E, de Witte T, Abraham NG: Heme induces the expression of adhesion molecules ICAM-1, VCAM-1, and E selectin in vascular endothelial cells. Proc Soc Exp Biol Med 1997;216:456-463.
23. Graca-Souza AV, Arruda MA, de Freitas MS, Barja-Fidalgo C, Oliveira PL: Neutrophil activation by heme: implications for inflammatory processes. Blood 2002;99:4160-4165.
24. Kim JH, Lee DW, Jung MH, Cho HS, Jeon DH, Chang SH, Park DJ: Macrophage depletion ameliorates glycerolinduced acute kidney injury in mice. Nephron Exp Nephrol 2014;128:21-29.
25. Komada T, Usui F, Kawashima A, Kimura H, Karasawa T, Inoue Y, Kobayashi M, Mizushina Y, Kasahara T, Taniguchi S, Muto S, Nagata D, Takahashi M: Role of NLRP3 Inflammasomes for Rhabdomyolysis-induced Acute Kidney Injury. Sci Rep 2015;5:10901.
26. Zager RA, Johnson AC, Hanson SY: Proximal tubular cytochrome c efflux: determinant, and potential marker, of mitochondrial injury. Kidney Int 2004;65:2123-2134.
27. Plotnikov EY, Chupyrkina AA, Pevzner IB, Isaev NK, Zorov DB: Myoglobin causes oxidative stress, increase of NO production and dysfunction of kidney's mitochondria. Biochim Biophys Acta 2009;1792:796-803.
28. Homsi E, Janino P, de Faria JB: Role of caspases on cell death, inflammation, and cell cycle in glycerolinduced acute renal failure. Kidney Int 2006;69:1385-1392.
29. Davis RJ: Signal transduction by the JNK group of MAP kinases. Cell 2000;103:239-252.
30. Ishizuka S, Yano T, Hagiwara K, Sone M, Nihei H, Ozasa H, Horikawa S: Extracellular signal-regulated kinase mediates renal regeneration in rats with myoglobinuric acute renal injury. Biochem Biophys Res Commun 1999;254:88-92.
31. Bonventre JV, Weinberg JM: Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol 2003;14:2199-2210.
32. Thomsen JH, Etzerodt A, Svendsen P, Moestrup SK: The haptoglobin-CD163-heme oxygenase-1 pathway for hemoglobin scavenging. Oxid Med Cell Longev 2013;2013:523652.
33. Nath KA, Haggard JJ, Croatt AJ, Grande JP, Poss KD, Alam J: The indispensability of heme oxygenase-1 in protecting against acute heme protein-induced toxicity in vivo. Am J Pathol 2000;156:1527-1535.
34. Otterbein LE, Bach FH, Alam J, Soares M, Tao Lu H, Wysk M, Davis RJ, Flavell RA, Choi AM: Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med 2000;6:422-428.
35. Berberat PO, Katori M, Kaczmarek E, Anselmo D, Lassman C, Ke B, Shen X, Busuttil RW, Yamashita K, Csizmadia E, Tyagi S, Otterbein LE, Brouard S, Tobiasch E, Bach FH, Kupiec-Weglinski JW, Soares MP: Heavy chain ferritin acts as an antiapoptotic gene that protects livers from ischemia reperfusion injury. FASEB J 2003;17:1724-1726.
36. Wegiel B, Otterbein LE: Go green: the anti-inflammatory effects of biliverdin reductase. Front Pharmacol 2012;3:47.
37. Gabow PA, Kaehny WD, Kelleher SP: The spectrum of rhabdomyolysis. Medicine (Baltimore) 1982;61:141-152.
38. Lippi G, Sanchis-Gomar F, Salvagno GL, Aloe R, Schena F, Guidi GC: Variation of serum and urinary neutrophil gelatinase associated lipocalin (ngal) after strenuous physical exercise. Clin Chem Lab Med 2012;50:1585-1589.
39. Antonucci E, Lippi G, Ticinesi A, Pigna F, Guida L, Morelli I, Nouvenne A, Borghi L, Meschi T: Neutrophil gelatinase-associated lipocalin (ngal): A promising biomarker for the early diagnosis of acute kidney injury (aki). Acta Biomed 2014;85:289-294.
40. Wang B, Chen G, Zhang J, Xue J, Cao Y, Wu Y: Increased neutrophil gelatinase-associated lipocalin is associated with mortality and multiple organ dysfunction syndrome in severe sepsis and septic shock. Shock 2015;44:234-238.
41. Koyner JL, Vaidya VS, Bennett MR, Ma Q, Worcester E, Akhter SA, Raman J, Jeevanandam V, OConnor MF, Devarajan P, Bonventre JV, Murray PT: Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. Clin J Am Soc Nephrol 2010;5:2154-2165.
42. Sever MS, Vanholder R, Lameire N: Management of crush-related injuries after disasters. N Engl J Med 2006;354:1052-1063.
43. Heyman SN, Greenbaum R, Shina A, Rosen S, Brezis M: Myoglobinuric acute renal failure in the rat: a role for acidosis Exp Nephrol 1997;5:210-216.
44. Brown CV, Rhee P, Chan L, Evans K, Demetriades D, Velmahos GC: Preventing renal failure in patients with rhabdomyolysis: do bicarbonate and mannitol make a difference J Trauma 2004;56:1191-1196.
45. Homsi E, Barreiro MF, Orlando JM, Higa EM: Prophylaxis of acute renal failure in patients with rhabdomyolysis. Ren Fail 1997;19:283-288.
46. Vanholder R, Sever MS, Erek E, Lameire N: Rhabdomyolysis. J Am Soc Nephrol 2000;11:1553-1561.
47. Ozguc H, Kahveci N, Akkose S, Serdar Z, Balci V, Ocak O: Effects of different resuscitation fluids on tissue blood flow and oxidant injury in experimental rhabdomyolysis. Crit Care Med 2005;33:2579-2586.
48. Lameire N, Van Biesen W, Vanholder R: Acute renal failure. Lancet 2005;365:417-430.
49. Sorrentino SA, Kielstein JT, Lukasz A, Sorrentino JN, Gohrbandt B, Haller H, Schmidt BM: High permeability dialysis membrane allows effective removal of myoglobin in acute kidney injury resulting from rhabdomyolysis. Crit Care Med 2011;39:184-186.
50. Naka T, Jones D, Baldwin I, Fealy N, Bates S, Goehl H, Morgera S, Neumayer HH, Bellomo R: Myoglobin clearance by super high-flux hemofiltration in a case of severe rhabdomyolysis: a case report. Crit Care 2005;9:R90-95.
51. Premru V, Kovac J, Buturovic-Ponikvar J, Ponikvar R: High cut-off membrane hemodiafiltration in myoglobinuric acute renal failure: a case series. Ther Apher Dial 2011;15:287-291.
52. Zhang L, Kang Y, Fu P, Cao Y, Shi Y, Liu F, Hu Z, Su B, Tang W, Qin W: Myoglobin clearance by continuous venous-venous haemofiltration in rhabdomyolysis with acute kidney injury: a case series. Injury 2012;43:619-623.
53. Tang W, Chen Z, Wu W, Qiu H, Bo H, Zhang L, Fu P: Renal protective effects of early continuous venovenous hemofiltration in rhabdomyolysis: improved renal mitochondrial dysfunction and inhibited apoptosis. Artif Organs 2013;37:390-400.
54. Swaroop R, Zabaneh R, Parimoo N: Plasmapheresis in a patient with rhabdomyolysis: a case report. Cases J 2009;2:8138.
55. Ronco C: Extracorporeal therapies in acute rhabdomyolysis and myoglobin clearance. Crit Care 2005;9:141-142.
56. Paller MS: Hemoglobin-and myoglobin-induced acute renal failure in rats: role of iron in nephrotoxicity. Am J Physiol 1988;255:F539-544.
57. Reeder BJ, Wilson MT: Desferrioxamine inhibits production of cytotoxic heme to protein cross-linked myoglobin: a mechanism to protect against oxidative stress without iron chelation. Chem Res Toxicol 2005;18:1004-1011.
58. Groebler LK, Liu J, Shanu A, Codd R, Witting PK: Comparing the potential renal protective activity of desferrioxamine B and the novel chelator desferrioxamine B-N-(3-hydroxyadamant-1-yl)carboxamide in a cell model of myoglobinuria. Biochem J 2011;435:669-677.
59. Kontoghiorghes GJ, Pattichi K, Hadjigavriel M, Kolnagou A: Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). Transfus Sci 2000;23:211-223.
60. Anderson BJ: Paracetamol (Acetaminophen): mechanisms of action. Paediatr Anaesth 2008;18:915-921.
61. Boutaud O, Moore KP, Reeder BJ, Harry D, Howie AJ, Wang S, Carney CK, Masterson TS, Amin T, Wright DW, Wilson MT, Oates JA, Roberts LJ, 2nd: Acetaminophen inhibits hemoprotein-catalyzed lipid peroxidation and attenuates rhabdomyolysis-induced renal failure. Proc Natl Acad Sci U S A 2010;107:2699-2704.
62. Luo J, Tsuji T, Yasuda H, Sun Y, Fujigaki Y, Hishida A: The molecular mechanisms of the attenuation of cisplatin-induced acute renal failure by N-acetylcysteine in rats. Nephrol Dial Transplant 2008;23:2198-2205.
63. Nitescu N, Ricksten SE, Marcussen N, Haraldsson B, Nilsson U, Basu S, Guron G: N-acetylcysteine attenuates kidney injury in rats subjected to renal ischaemia-reperfusion. Nephrol Dial Transplant 2006;21:1240-1247.
64. Shimizu MH, Coimbra TM, de Araujo M, Menezes LF, Seguro AC: N-acetylcysteine attenuates the progression of chronic renal failure. Kidney Int 2005;68:2208-2217.
65. Kim JH, Lee SS, Jung MH, Yeo HD, Kim HJ, Yang JI, Roh GS, Chang SH, Park DJ: N-acetylcysteine attenuates glycerol-induced acute kidney injury by regulating MAPKs and Bcl-2 family proteins. Nephrol Dial Transplant 2010;25:1435-1443.
66. Machlin LJ, Bendich A: Free radical tissue damage: protective role of antioxidant nutrients. FASEB J 1987;1:441-445.
67. Huerta-Alardin AL, Varon J, Marik PE: Bench-to-bedside review: Rhabdomyolysis -an overview for clinicians. Crit Care 2005;9:158-169.
68. Groebler LK, Wang XS, Kim HB, Shanu A, Hossain F, McMahon AC, Witting PK: Cosupplementation with a synthetic, lipid-soluble polyphenol and vitamin C inhibits oxidative damage and improves vascular function yet does not inhibit acute renal injury in an animal model of rhabdomyolysis. Free Radic Biol Med 2012;52:1918-1928.
69. Rodrigo R, Bosco C, Herrera P, Rivera G: Amelioration of myoglobinuric renal damage in rats by chronic exposure to flavonol-rich red wine. Nephrol Dial Transplant 2004;19:2237-2244.
70. Aydogdu N, Atmaca G, Yalcin O, Taskiran R, Tastekin E, Kaymak K: Protective effects of L-carnitine on myoglobinuric acute renal failure in rats. Clin Exp Pharmacol Physiol 2006;33:119-124.
71. Van Rooijen N, Sanders A: Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994;174:83-93.
72. Ko GJ, Boo CS, Jo SK, Cho WY, Kim HK: Macrophages contribute to the development of renal fibrosis following ischaemia/reperfusion-induced acute kidney injury. Nephrol Dial Transplant 2008;23:842-852.
73. Liu N, Tolbert E, Pang M, Ponnusamy M, Yan H, Zhuang S: Suramin inhibits renal fibrosis in chronic kidney disease. J Am Soc Nephrol 2011;22:1064-1075.
74. Korrapati MC, Shaner BE, Schnellmann RG: Recovery from glycerol-induced acute kidney injury is accelerated by suramin. J Pharmacol Exp Ther 2012;341:126-136.
75. Tsai TJ, Lin RH, Chang CC, Chen YM, Chen CF, Ko FN, Teng CM: Vasodilator agents modulate rat glomerular mesangial cell growth and collagen synthesis. Nephron 1995;70:91-99.
76. Strutz F, Heeg M, Kochsiek T, Siemers G, Zeisberg M, Muller GA: Effects of pentoxifylline, pentifylline and gamma-interferon on proliferation, differentiation, and matrix synthesis of human renal fibroblasts. Nephrol Dial Transplant 2000;15:1535-1546.
77. Savic V, Vlahovic P, Djordjevic V, Mitic-Zlatkovic M, Avramovic V, Stefanovic V: Nephroprotective effects of pentoxifylline in experimental myoglobinuric acute renal failure. Pathol Biol (Paris) 2002;50:599-607.
78. de Almeida DC, Donizetti-Oliveira C, Barbosa-Costa P, Origassa CS, Camara NO: In search of mechanisms associated with mesenchymal stem cell-based therapies for acute kidney injury. Clin Biochem Rev 2013;34:131-144.
79. Duffy MM, Griffin MD: Back from the brink: a mesenchymal stem cell infusion rescues kidney function in acute experimental rhabdomyolysis. Stem Cell Res Ther 2014;5:109.
80. Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, Granton J, Stewart DJ, Canadian Critical Care Trials G: Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One 2012;7:e47559.
81. Jeong H, Yim HW, Cho YS, Kim YI, Jeong SN, Kim HB, Oh IH: Efficacy and safety of stem cell therapies for patients with stroke: a systematic review and single arm meta-analysis. Int J Stem Cells 2014;7:63-69.
82. Taniguchi T: Cytokine adsorbing columns. Contrib Nephrol 2010;166:134-141.
83. Peng ZY, Carter MJ, Kellum JA: Effects of hemoadsorption on cytokine removal and short-term survival in septic rats. Crit Care Med 2008;36:1573-1577.
84. Basu R, Pathak S, Goyal J, Chaudhry R, Goel RB, Barwal A: Use of a novel hemoadsorption device for cytokine removal as adjuvant therapy in a patient with septic shock with multi-organ dysfunction: A case study. Indian J Crit Care Med 2014;18:822-824.
85. Pattnaik SK, Panda B: CytoSorb-friend or foe!! Indian J Crit Care Med 2015;19:296.
86. Chander V, Chopra K: Molsidomine, a nitric oxide donor and L-arginine protects against rhabdomyolysisinduced myoglobinuric acute renal failure. Biochim Biophys Acta 2005;1723:208-214.
87. Newaz MA, Oyekan AO: Vascular responses to endothelin-1, angiotensin-II, and U46619 in glycerol-induced acute renal failure. J Cardiovasc Pharmacol 2001;38:569-577.
88. Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M, Kieswich J, Allen D, Harwood S, Raftery M, Thiemermann C, Yaqoob MM: Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004;15:2115-2124.
89. Yang FL, Subeq YM, Chiu YH, Lee RP, Lee CJ, Hsu BG: Recombinant human erythropoietin reduces rhabdomyolysis-induced acute renal failure in rats. Injury 2012;43:367-373.
90. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P, European Organisation for R, Treatment of Cancer Taskforce for the E: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258-270.